TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01137812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Description: Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphonylurea
Description: Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Study: NCT04261595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dates fruit as functional Food
Description: Two groups will receive Dates; The number per group is dependant on the child age. For children aged 3-6 years; they will receive the minimum numbers of dates (3 pieces). For children aged more than 6-12 years will receive 5 pieces of Dates the choice of the minimum numbers of dates (3 pieces) in this current trial is based on a study that was done by Al Jaouni and his colleagues, 2019 which proved the effects of three pieces of Ajwa on infection, hospitalization, and survival among 26 pediatric cancer patients in a university hospital; for which their treatment outcome was improved due to their intake of this amount of Ajwa during their standard treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dates fruit as functional Food
Description: Two groups will receive Dates; The number per group is dependant on the child age. For children aged 3-6 years; they will receive the minimum numbers of dates (3 pieces). For children aged more than 6-12 years will receive 5 pieces of Dates the choice of the minimum numbers of dates (3 pieces) in this current trial is based on a study that was done by Al Jaouni and his colleagues, 2019 which proved the effects of three pieces of Ajwa on infection, hospitalization, and survival among 26 pediatric cancer patients in a university hospital; for which their treatment outcome was improved due to their intake of this amount of Ajwa during their standard treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral modification and stimulation
Description: Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral modification and stimulation
Description: Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral modification and stimulation
Description: Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutritional Guidance
Description: The nutritional education sessions are based on educating parents on providing their autistic children with a nutritious, balanced diet. Because children with ASD often have restricted diets as well as difficulty sitting through meal times, they may not be getting all the nutrients they need, particularly calcium and protein
Study: NCT01843556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022 Tape Formulation
Description: E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
Study: NCT03737864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: The patient navigator will provide support to patients upon discharge and will maintain regular contact either in person or by phone at a minimum of once per week for 30 days, or until the patient successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interviewing (MI)
Description: A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
Study: NCT00947102

Intervention type: OTHER
Intervention: Observation
Study: NCT00749086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon kyphoplasty
Description: Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertebroplasty
Description: Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
Study: NCT03759652

Intervention type: BEHAVIORAL
Intervention: before-after study
Description: The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).

Intervention type: BEHAVIORAL
Intervention: before-after study
Description: The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).
Study: NCT02334267

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: GranuFlo
Description: Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
Study: NCT04261595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutritional Guidance
Description: The nutritional education sessions are based on educating parents on providing their autistic children with a nutritious, balanced diet. Because children with ASD often have restricted diets as well as difficulty sitting through meal times, they may not be getting all the nutrients they need, particularly calcium and protein
Study: NCT02334267

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: NaturaLyte
Description: Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
Study: NCT01793987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coblation polypectomy
Study: NCT01090557

Intervention type: OTHER
Intervention: Collection of exhaled breath
Description: balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement

Intervention type: OTHER
Intervention: Collection of exhaled breath
Description: balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement

Intervention type: OTHER
Intervention: Collection of exhaled breath
Description: balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
Study: NCT03744689

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane block
Description: Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham block
Description: Sham block will be done with serum physiologic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20 ml 0,25% Bupivacaine will be used for block performances

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PCA
Description: Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
Study: NCT01416311

Intervention type: DRUG
Intervention: Eltrombopag
Study: NCT02788539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Whole Lives Website
Description: OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
Study: NCT02660697

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction site development
Description: In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
Study: NCT03026517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenformin
Study: NCT02383173

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic Implementation Approach
Description: Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation Approach
Description: Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites
Study: NCT01804907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Behavioral Modification
Study: NCT01667614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolacone 25 mg tablets added to losartan
Description: spironolactone 25 mg once daily added to losartan
Study: NCT03215615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: Coronally advanced flap for root coverage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: Coronally advanced flap for root coverage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: Coronally advanced flap for root coverage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: Coronally advanced flap for root coverage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Etch adhesive
Description: Total-etch adhesive system (two step)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Etch adhesive
Description: Total-etch adhesive system (two step)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Universal Adhesive
Description: One-step self-etching adhesive system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Universal Adhesive
Description: One-step self-etching adhesive system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nanofilled Composite
Description: Partial nanofilled-resin composite restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nanofilled Composite
Description: Partial nanofilled-resin composite restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro-Hybrid Composite
Description: Partial micro-hybrid composite restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro-Hybrid Composite
Description: Partial micro-hybrid composite restoration
Study: NCT02412319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-HBV placenta transfer factor injection
Description: Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
Study: NCT02575625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test for biological assessment of liver function
Description: Blood test for biological assessment of liver function

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Liver MRI
Study: NCT01713738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: infusion of 4 weekly doses of 375 mg/m2 rituximab
Study: NCT01297244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Study: NCT01531153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: 8mg or 16mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo dose.
Study: NCT01324180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m\^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: * 10 mg/m\^2/day divided BID~* Take dexamethasone by mouth days 2-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: * 2500 IU's/m\^2/day~* Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~* If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~* Patients will receive Erwinase® 25,000 IU/m\^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m\^2/day IV over 15 minutes on day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal chemotherapy
Description: IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age.
Study: NCT02744768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Upon induction:~patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary.
Study: NCT01576393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Family Therapy
Description: 12 home-based family therapy sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: office-based family therapy
Description: 12 office-based family therapy sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: WHE
Description: 12 Women's Health Education Sessions
Study: NCT02890888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen treatment
Description: Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
Study: NCT00038246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine
Description: 140 mg by mouth (po) three times a day on Days 1-5, 8-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Description: 100 mg/m\^2 by vein (IV) over 3 hours Day 3 and Day 10
Study: NCT05202431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment adherence
Description: The patients were reminded to take drug by patient training, telephone follow-up, and daily sms. It was determined that the effect of the training and telephone follow-up provided to the TB patients and contacts on the treatment adherence.
Study: NCT03792997

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combination therapy for high peripheral NK cells
Description: lipid emulsion \& prednisolone \& LMWH

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination therapy for high peripheral NK cells
Description: lipid emulsion \& prednisolone \& LMWH
Study: NCT04094805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocaltrol
Description: Rocaltrol 0.25 μg daily for 1 month; HD-DXM (orally at 40 mg daily for 4d )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocaltrol
Description: Rocaltrol 0.25 μg daily for 1 month; HD-DXM (orally at 40 mg daily for 4d )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: HD-DXM (orally at 40 mg daily for 4d )
Study: NCT01124539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
Description: IV AR-67 administered once daily for 5 days on an every 21-day cycle
Study: NCT02874131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive processing therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive processing therapy
Study: NCT05192876

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Outcomes and adverse events using radiation therapy